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Abstract
Background: The peptidyl prolyl cis/trans isomerase (PPIase) Parvulin (Par14/PIN4) is highly
conserved in all metazoans and is assumed to play a role in cell cycle progression and chromatin
remodeling. It is predominantly localized to the nucleus and binds to chromosomal DNA as well as
bent oligonucleotides in vitro.
Results: In this study we confirm by RT-PCR the existence of a longer Parvulin isoform expressed
in all tissues examined so far. This isoform contains a 5' extension including a 75 bp extended open
reading frame with two coupled SNPs leading to amino acid substitutions Q16R and R18S. About
1% of all Parvulin mRNAs include the novel extension as quantified by real-time PCR. The human
Parvulin promoter is TATA-less and situated in a CpG island typical for house keeping genes. Thus,
different Parvulin mRNAs seem to arise by alternative transcription initiation. N-terminally
extended Parvulin is protected from rapid proteinaseK degradation. In HeLa and HepG2 cell lysates
two protein species of about 17 and 28 KDa are detected by an antibody against an epitope within
the N-terminal extension. These two bands are also recognized by an antibody towards the PPIase
domain of Parvulin. The longer Parvulin protein is encoded by the human genome but absent from
rodent, bovine and non-mammalian genomes.
Conclusion: Due to its molecular weight of 16.6 KDa we denote the novel Parvulin isoform as
Par17 following the E. coli Par10 and human Par14 nomenclature. The N-terminal elongation of
Par17-QR and Par17-RS suggests these isoforms to perform divergent functions within the
eukaryotic cell than the well characterized Par14.
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Background
Members of the parvulin family of peptidyl prolyl cis/
trans isomerases (EC 5.2.1.8) are involved in mitotic reg-
ulatory mechanisms and cell proliferation [1-4]. The
human genome only encodes two parvulin proteins –
Pin1 and Parvulin. Pin1 is a well studied mitotic regulator
involved in cell cycle and transcriptional regulation
[1,4,5]. Overexpression of Pin1 was found in several
tumor types [6,7]; inhibition of this enzyme leads to
apoptosis in a Ras-transformed cell line [8]. The second
member of the parvulin PPIase family, the 14 KDa protein
Parvulin14 [9,10] (Par14 or PIN4), is assumed to be
involved in cell cycle progression or chromatin remode-
ling [11,12]. Pin1 and Par14 sequences are found in all
multi-cellular organisms from N. crassa and C. elegans to
man, whereas yeasts contain only one parvulin homolog
called Ess1. The lethal phenotype of Ess1 deletion can
only be rescued by human Pin1 but not by hPar14 [13]
suggesting divergent cellular functions for the two human
parvulins.
Although the C-terminal PPIase domains of human Pin1
and Par14 proteins are similar both in sequence and in
three-dimensional structure, their N-terminal domains
differ significantly. Whereas hPin1 carries an N-terminal
WW motif [2,5,14], the basic domain of hPar14 (compris-
ing the first 35 amino acids) is unfolded in solution [15].
Par14 is localized in cytosol and nucleus with deletion
studies pointing to a nuclear import signal located within
the basic N-terminal part [12]. Within the nucleus, Par14
was reported to bind to pre-ribosomal ribonucleoprotein
particles [16], and sequence specifically to bent double
stranded DNA [12]. Such bent A/T rich segments of DNA
are supposed to dictate nucleosome positioning and play
a role in transcription initiation. The N-terminal part of
Par14 is necessary for high affinity DNA binding. Phos-
phorylation within this region at Ser19 regulates nuclear
localization and DNA binding [11].
Within the N-terminal basic domain Par14 shows 45%
homology to the region surrounding the chromatin
unfolding domain of HMGN proteins [12,15], whose res-
idues are involved in contacts to nucleosomal DNA. A
structural feature called the HMGB domain which is well
known from transcription factors LEF-1 or SRY can be
found as part of the catalytic domain within the first
alpha-helix of the PPIase domain of Parvulin [12]. This
motif includes a hydrophobic patch (Ile51, Met52 and
Met55 in Par14) that conforms to a minor groove binding
mode. For the transcription factor LEF-1 these residues
were shown to be essential for contacting DNA within the
minor groove and for inducing bent DNA structures.
Despite all these data, there are several open questions
concerning the cellular function of Parvulin. In this study
we confirm by RT-PCR the existence of a longer Parvulin
isoform that has an extension at the 5' end including a 75
bp extended open reading frame. As E.coli  Par10 and
human Par14 are numbered according to their molecular
weight, we refer to the novel Parvulin isoform as Par17.
A – Schematic representation of the human Parvulin gene Figure 1
A – Schematic representation of the human Parvulin 
gene. The mRNA is spliced together from four exons 
between 43 and 723 bp in length. The size of all introns and 
exons is given in base pairs (bp). The longer Parvulin mRNA 
contains a 92 bp extension at the 5' side depicted in white. 
Primers used for RT-PCR are indicated by arrows. Primers 
246 and 247 are complementary to the sequences around 
the two start ATG codons, 248 binds at the sequence 
around the TAA stop codon. B – RT-PCR products from 
different cDNA samples. RT-PCR products with mRNA 
from liver, kidney and Caco-2 cells after 30 amplification 
cycles. Primers 246 and 248 yield a 488 bp PCR product only 
on those Par14 mRNAs with 5' extension. Primers 247 and 
248 give rise to a 385 bp DNA fragment with all Par14 
mRNAs. All longer RT-PCR products were eluted from the 
gel and sequenced. C – First 150 nucleotides of the elon-
gated Parvulin mRNA. Two start ATG codons are indi-
cated in bold capital letters. The sequence of Parvulin 
common to both originally described cDNAs by Uchida et al. 
[GenBank:AF143096] [3] and Rulten et al. [Gen-
Bank:AB009690] [9] begins at the caa codon depicted in 
bold. The peptide sequence used for antibody production is 
shaded in grey. Two SNPs are shown leading to amino acid 
substitutions Q16R and R18S.BMC Molecular Biology 2006, 7:9 http://www.biomedcentral.com/1471-2199/7/9
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Results and discussion
Identification and quantification of new isoforms of 
human Parvulin mRNA
Recently, the Parvulin RefSeq [17] entry for human Parvu-
lin [GenBank:NM_006223.2] was updated by incorporat-
ing a 5' extension of about 90 nucleotides relative to the
original database entries [9,10]. This sequence was only
encoded by one expressed sequence tag (EST) [Gen-
Bank:AU098526]. To prove this extension to occur within
cells, we performed RT-PCR on human mRNAs from dif-
ferent tissues. As the 5' extension contains an additional
start codon 75bases upstream of the original start codon,
primers were designed to confirm the occurrence of both
the short Par14 and the extended open reading frames by
RT-PCR. A schematic representation of the Parvulin
mRNA together with the positioning of primers is given in
Figure 1A. The PCR products corresponding to the 5'
extension and total Parvulin mRNA were detected in all
tissues tested so far. The PCR signal for the 5' extension is
much weaker than the total Parvulin PCR product. RT-
PCR bands from liver, kidney and Caco-2 cDNAs are
shown exemplarily in Figure 1B.
All 488 bp DNA fragments corresponding to the elon-
gated Parvulin mRNA were eluted from gels and
sequenced. Thereby, two nonsynonymous single nucle-
otide polymorphisms (SNPs) leading to two amino acid
substitutions Q16R and R18S were detected within the 5'
extension that are also referenced in the NCBI SNP data-
base as rs6525589 and rs7058353, respectively. Out of 14
different cDNAs sequenced, only two did contain these
mutations, the liver and kidney cDNA samples used in
this study. We only have observed the coupled occurrence
of these two SNPs. In addition, these two cDNAs had the
silent GCC to GCT mutation at Ala93 (rs16991466)
within the known part of the Par14 mRNA. The first 176
nucleotides of the elongated Parvulin mRNA together
with the detected coupled SNPs are depicted in Figure 1C.
To quantify relative amounts of different Parvulin mRNA
isoforms, real-time PCR primers that detect the novel 5'
extension and total Parvulin mRNA (indicated in Figure
1A) were designed and confirmed to yield uniform PCR
products by agarose gel electrophoresis. mRNAs from dif-
ferent sources were extensively treated with DNase to
degrade any traces of genomic DNA and reverse tran-
scribed. The above mentioned primers were then used to
perform real-time PCR with SYBR Green detection on the
resulting cDNAs to analyze the extended and total Parvu-
lin messages. The melting curves of the generated PCR
products are shown in Figure 2A. Therein the maxima rep-
resent the melting points of the corresponding PCR prod-
ucts with 79.5°C for the fragment corresponding to total
Parvulin mRNAs. The melting curves for the PCR products
Real-time PCR quantification of human parvulin mRNA isoforms Figure 2
Real-time PCR quantification of human parvulin mRNA isoforms. A. Dissociation curves for total parvulin mRNA 
(total) and long isoforms (indicated with QR and RS). B. Fraction of long parvulin mRNA isoform within amount of total Parvu-
lin mRNA in cDNAs from the tissues indicated.BMC Molecular Biology 2006, 7:9 http://www.biomedcentral.com/1471-2199/7/9
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originating from the Parvulin 5' extension can be grouped
into two ensembles with about 82°C and 83°C melting
temperatures. The former corresponds to the above men-
tioned QR variant; the elevated melting point of the latter
can be explained by two AT base pairs changed to GC
bases in the RS variant. Thus, the primers used in this
study should enable fast real-time SNP detection of RS
and QR genotypes in other human cDNAs or patient sam-
ples.
Relative amounts of long Parvulin mRNA and total Parvu-
lin mRNA were then calculated based on the real-time
PCR data. The fraction of the long isoform within total
Parvulin mRNA is given in Figure 2B ranging from 0.2%
in the skeletal muscle cDNA sample used for this study to
2.6% in a cDNA from the submandibularis gland.
An elongated Parvulin isoform is expressed in human cell 
lines
As not every ATG codon is necessarily used for translation
initiation, we attempted to translate the different coding
sequences of Parvulin in vitro. Therefore, the open reading
frames for the QR and RS Parvulin variants as well as
Par14 were TOPO-cloned into the vector pCR-4 and 35S-
methionine labeled in a T7 polymerase/reticulocyte in
vitro transcription/translation system Figure 3A. A 14KDa
translation product was produced both from the short
and elongated Parvulin templates suggesting that the con-
text of the second ATG is suited for translation initiation
despite the lack of a classical Kozak sequence [18]. In
addition, QR and RS Parvulin templates yielded a transla-
tion product of about 17KDa in agreement with a theoret-
ical molecular weight of 16,6 KDa. Therefore, we refer to
the novel Parvulin isoform from now on as Par17 accord-
ing to the denotation of other parvulins [10,19]. Although
Parvulin is also referred to as PIN4 in databases we prefer
the name Par14/Par17 to avoid confusion with a putative
auxin efflux carrier protein from Arabidopsis that is inci-
dentally named PIN4, too.
The longer Parvulin mRNA encodes a protein N-termi-
nally extended by 25 amino acids. tBLAST searches with
this N-terminal protein sequence as query neither yield
significant similarities in the nr database of GenBank nor
at other loci within the human genome. The extension is
predicted to adopt an additional amphipatic alpha-helix
in the protein [20]. Rulten et al. and Sekerina et al.
reported fast degradation of the basic and flexible domain
of Par14 by Chymotrypsin and an E. coli protease, respec-
tively [9,15]. We were interested, whether the amphipatic
helix might be able to stabilize the degradable protein part
by binding to the catalytic domain or by masking it. Thus,
the structural integrity of Par17 was tested by limited pro-
teinaseK digestion. At minor enzyme concentrations
(0.01 µg/ml) the 35S-methionine labeled short Parvulin
is degraded leaving over the catalytic domain only (Figure
3B). For degradation of the long protein isoforms at least
five-fold higher protease concentrations are needed. This
indicates that the N-terminal elongation seems to protect
the protease sensitive basic region from being digested
rapidly.
Next, we wanted to prove the expression of the elongated
Parvulin isoform in human cells. Therefore, a polyclonal
antibody was raised against an epitope within the N-ter-
minal extension of human Par14 that was shaded in gray
in Figure 1C. This antibody recognized both the Q16/R18
and R16/S18 isoforms of the elongated Parvulin protein
overexpressed in E. coli with slightly higher affinity
towards the RS form (figure 3D) but does not recognize
GFP fused Par14 expressed in HeLa cells that lacks the N-
terminal extension (figure 3E). Thus, the expression of the
elongated protein can be detected irrespective of the par-
ticular genotype. In most fresh protein lysates from HeLa
and HepG2 cells, only the 28 KDa species was detected
(Figure 3C). In addition, we detected a 17 KDa species in
other HeLa and HepG2 lysates. After repeated freeze-thaw
cycles, this second protein species at 17 KDa gained inten-
sity with the 28 KDa band appearing much weaker (Figure
4B). Despite the presence of protease inhibitors, this
observation could be attributed to the already reported
high protease sensitivity of Parvulin [9,15].
An antibody against the PPIase domain was used to detect
Parvulin isoforms in HepG2 and HeLa cell lysates (figure
4A as described in previous studies [11,12]. This antibody
recognized Par14 at about 14 KDa, one protein species
with an apparent molecular weight of nearly 17 KDa and
two bands larger than 22 KDa indicating that all these
bands do contain Parvulin's PPIase domain. This blot was
stripped and re-probed with the antibody towards the N-
terminal extension that was affinity purified on a CNBr-
coupled Par17-QR/RS sepharose column to enhance spe-
cificity. Again, a 17 KDa and two protein species above 22
KDa were detected. This antibody did not recognize the
Par14 band. This shows that Par17 is present within
human cells both in modified and unmodified forms.
The 28 KDa protein species described above could be
explained with an SDS stable protein dimer. Such dimers
are described for hydrophobic, transmembrane proteins.
As extended hydrophobic regions could not be detected in
the primary structure of Par17 we excluded the assump-
tion of a Parvulin dimer. Alternatively, the difference of
about 10 KDa between in vitro translated Par17 and the
28KDa immunoreactive protein species in cell lysates sug-
gests post-translational modification with a proteinous
tag. To test this, Western blots were re-probed with anti-
bodies against SUMO1, SUMO2/3 and Ubiquitin. Neither
SUMO1 nor Ubiquitin conjugated species could beBMC Molecular Biology 2006, 7:9 http://www.biomedcentral.com/1471-2199/7/9
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A – In vitro translation of Parvulin isoforms Figure 3
A – In vitro translation of Parvulin isoforms. Open reading frames for Par17-QR, Par17-RS and Par14 were TOPO-
cloned into the vector pCR-4 and 35S-methionine labeled in an in vitro transcription/translation reaction. Reaction products 
were separated by 17.5% SDS-PAGE following autoradiography. B – Proteinase K digestion of Parvulin isoforms. Equal 
amounts of 35S-methionine labeled Par17-QR, Par17-RS and Par14 were incubated with increasing concentrations of protein-
aseK (PK) for 30 min at 10°C. Enzyme concentrations are given in µg/ml. Reactions were stopped by an excess of PMSF, sepa-
rated by SDS-PAGE and subjected to autoradiography. C – Western blots of cell lysates. Western blot of HepG2 (lane 1 
and 3) and HeLa (lane 2 and 4) cell lysates. Proteins were separated by SDS-PAGE with MES as running buffer and SeeBlue2 as 
protein standard, transferred to nitrocellulose membranes. Blots were incubated with pre-immune (lane 1 and 2) or anti-Par17 
serum (lane 3 and 4; both at 500-fold dilution). D – The newly raised antibody Ab-EXT recognizes Par17-RS and -QR. 
Coding sequences for Par17-RS and -QR were subcloned in the pET-28 vector with N-terminal His6 tag and expressed in E. 
coli. Lysates were subjected to reducing SDS-PAGE in MES buffer and SeeBlue2 as protein standard, transferred to nitrocellu-
lose membranes and incubated with the anti-Par17 antibody. -, before IPTG induction; RS, Par17-RS lysates; QR, Par17-QR 
lysates. Coomassie stained gel of lysates to show equal loading. Par17 fusions with His6 tag and thrombin cleavage sites show 
apparent molecular weights of about 22 KDa in SDS-PAGE. The induction band in E. coli lysates and the corresponding band 
recognized by Ab-EXT are labeled with arrows. The lower migrating band may be caused by proteolytic degradation. E – Ab-
EXT does not recognize GFP-Par14. Par14 coding sequence was expressed as GFP fusion in HeLa cells (lane 3). Lane 1 
and 2 are HeLa cell lysates not transfected with this construct. Lysates were subjected to reducing SDS-PAGE in Tris-glycine 
buffer with MagicMark as protein standard, transferred to nitrocellulose membranes and incubated with anti-Par17 and anti-
GFP antibodies. Coomassie stained gel of lysates to show equal loading.BMC Molecular Biology 2006, 7:9 http://www.biomedcentral.com/1471-2199/7/9
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detected in the range between 20 and 40 KDa, only one
band of 28KDa recognized by the anti-SUMO2/3 anti-
body overlaid with the Parvulin band suggesting a conju-
gate between Par17 and SUMO2 or SUMO3 (Figure 4C).
As the fast degradation of the 28KDa protein species pre-
vented co-immunoprecipitation studies a final proof for
the presence of a Par17-SUMO2/3 conjugate is still miss-
ing.
The above mentioned polyclonal antibody against the iso-
lated PPIase domain of Par14 was also used in previously
performed Western blot studies of human cell lysates
(Surmacz et al. and Reimer et al.). In both studies, there
was a protein species detected at 28 KDa in addition to the
Par14 band. In addition, Reimer et al. applied HEK293
cell lysates to DNA-cellulose; bound proteins were eluted
by increasing salt concentrations. Parallel to the detected
Par14 band, another protein species was clearly visible at
about 28 KDa which we now have identified as modified
Par17. Therefore, we propose that Par17 may be able to
bind genomic DNA in a similar manner to Par14.
Transcriptional initiation at the human Parvulin promoter
The present study shows that in addition to the original
Par14 protein elongated isoforms of Parvulin are
expressed in human cells. The question arises whether
these isoforms are encoded by alternative open reading
frames. A genome wide BLAST search revealed sequences
on chromosome 1 and 15 that show a high degree of
sequence similarity to the well known Parvulin locus on
chromosome Xq13 with the gene name PIN4. As they do
not encode an N-terminal elongation and are only 87%
(chromosome 1) and 97% (chromosome 15) identical to
the described Parvulin sequence, these putative pseudo-
genes are not responsible for the occurrence of the iso-
forms in human tissues observed in our studies. Therefore
we conclude that the different isoforms must be encoded
by the PIN4 gene on chromosome Xq13.
The sequence preceding the transcription start site dis-
plays an extraordinarily high CpG ratio (0.864) and a GC
content of 51.6% (calculated for 200 bp upstream of the
first ATG codon), but lacks conserved TATA boxes and
downstream promoter elements. Only one sequence
motif immediately upstream of the first nucleotides of the
longest EST shows some similarity to the consensus initi-
ator sequence [21]. TATA-less promoters within CpG
islands are typical for housekeeping genes. They lack one
strong promoter but instead contain several weak pro-
moter elements [21] resulting in more than one transcrip-
tion initiation sites.
Using the extended cDNA sequence for human Parvulin
as query, the EST database of GenBank was searched by
BLAST [22]. For alignment only EST clones sequenced
from their 5' end exceeding an overlap of 50 nt with the
original cDNA entry of Uchida et al. were taken [10].
Intron containing ESTs were removed manually from this
collection, thereby excluding one 5' extended EST [Gen-
Bank:BI915994]. From the remaining 70 database entries
only the above mentioned AU098526 encoded the long
Detection of Par17 in cell lysates Figure 4
Detection of Par17 in cell lysates. A. Western blot of 
HeLa and HepG2 cell lysates. 10 and 50 µg HeLa (lane 1 and 
2) and 10 and 50 µg HepG2 (lane 3 and 4) cell extracts were 
separated by SDS-PAGE with Tris-glycine as running buffer 
and transferred to nitrocellulose membranes. SeeBlue2 was 
used as protein standard. Blots were incubated with Ab-PPI-
ase (polyclonal antibody against Parvulin's PPIase domain as 
described [11,12], stripped by 2% SDS at 65°C and re-
probed with affinity purified Ab-EXT (against the N-terminal 
extension). Coomassie stained membrane is shown as load-
ing control. B. Fresh protein samples (lane 1) as well as sam-
ples subjected to repeated freeze-thaw cycles (lane 2) were 
analyzed by Western blots using anti-Par17 antiserum. C; 
HeLa cell extracts were separated by SDS-PAGE with Tris-
glycine as running buffer, transferred to nitrocellulose and 
incubated with antibodies against SUMO-1 (lane1), SUMO-2/
3 (lane2) and Ubiquitin (lane3). Magic Mark was used as pro-
tein standard.BMC Molecular Biology 2006, 7:9 http://www.biomedcentral.com/1471-2199/7/9
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isoform corresponding to 1.5% of all sequences. This ratio
between long and total Parvulin mRNA is in good agree-
ment with our real-time data. Thus, both a short and an
extended version of Parvulin mRNA occur within human
cells. Taken the short length of Parvulin mRNAs of about
1 kB, we assume most if not all of these EST sequences to
be full length. Therefore, we aligned all Parvulin ESTs
sequenced from the 5' end which should be indicative for
the initiation of transcription at the Parvulin locus. All
ESTs differed to a certain extent in their 5' start. These dif-
ferent transcript starting points are in agreement with
transcriptional initiation from different weak initiator
points within a CpG island promoter that give raise to dif-
ferent Parvulin isoforms.
Parvulin genes in other organisms
The PPIase sequence of Par14 is very well conserved from
N. crassa and C. elegans to man with identities of 54.2%
and 82.3% compared to the human sequence. Therefore
it was interesting to search for extended Parvulin variants
in other organisms as well. Genomic Parvulin sequences
were available from 13 different species http://
www.ensembl.org which were compared with regard to
additional coding regions preceding the Par14 coding
sequence. A sequence from Canis familiaris more likely
resembled the above mentioned Parvulin pseudogene
and was not further analyzed. Genomic sequences from
chimp and chicken only contained the last two of the four
Parvulin exons with otherwise very similar exon length.
Despite all efforts, no more upstream sequence informa-
tion was available for these organisms from internet
resources. Even the recently published improved chimp
sequence only contains Parvulin exons three and four
[23]. With the exception of C.elegans and insects, all Par-
vulin genes were identical in their genomic structure. They
all contained one or more additional start codons within
an area 200 bp upstream of the Par14 ATG, however
nowhere – not even in mammals such as Mus musculus or
Bos taurus – these ATGs resulted in extended open reading
frames with similarities to human Par17 (Figure 5). It will
be especially interesting to search for Par17 within an
improved version of the chimp genome in the near future.
In contrast to the ubiquitous occurrence of Par14, the
expression of the elongated isoform Par17 seems to be
limited to some mammals with proven expression up to
now only in Homo sapiens.
Conclusion
Par14 is highly conserved in all metazoans. Human Par-
vulin mRNA is expressed in all tissues examined so far
pointing to ubiquitous expression. The TATA-less Parvu-
lin promoter is situated in a CpG island typical for house
keeping genes; such promoters often contain several weak
transcription start points. At least in humans this alterna-
tive transcription initiation gives raise to multiple mRNA
isoforms which could be proven by RT- and real-time
PCR. These mRNAs encode the formerly known Par14 as
well as N-terminally extended Par17. This longer protein
is expressed in HeLa and HepG2 cells and is probably
post-translationally modified. Its solution structure and
catalytic properties as well as interactions with possible
partners can now be addressed.
Methods
Bioinformatics
The EST databases of GenBank were searched by BLAST
http://www.ncbi.nlm.nih.gov/BLAST/ for EST sequences
with 5' extensions relative to the original cDNA entry
[GenBank:AB009690] [10]. Therefore, nucleotides 1 to
500 from the RefSeq entry for Parvulin [Gen-
Alignment of Parvulin genomic DNA sequences from different species Figure 5
Alignment of Parvulin genomic DNA sequences from different species. Genomic sequences from Homo sapiens, Bos 
taurus, Mus musculus and Xenopus tropicalis are aligned with the ATG start codon of Par14 common to all these sequences. The 
human sequence contains 5' to the Par14 coding sequence two additional in-frame ATG codons (highlighted in blue). The only 
other 5' ATG codon is present in the Bos taurus sequence; it is out of frame and followed by a TAA stop codon (both under-
lined). All in-frame stop codons are marked in red. Only the human sequence displays an extended open reading frame, both as 
QR and RS isoform (SNPs highlighted in grey).
Homo sapiens                                                         G      C
Genomic GTTTAGGACATGCCCATGGCGGGGCTTCTAAAGGGGCTTGTACGGCAACTGGAGCAGTTCAGAGTTCAACAACAAGCTTCCAAGATGCCGCCCAAAGGA
Protein     V Stp D M  P  M  A  G  L  L  K  G  L  V  R  Q  L  E  Q  F  R  V  Q  Q  Q  A  S  K  M  P  P  K  G 
                                                             R     S
Bos taurus 
Genomic CTATGTTTAGGACACACCAGTGGGGCCTGAAGGGGCTTTGTGCGGCAACCTAAGCAGTTGAGAGTTCAACGGCAGACTTTGGAAATGCCCCCGAAAGGA
Protein  L  C  L  G  H  T  S  G  A Stp R  G  F  V  R  Q  P  K  Q  L  R  V  Q  R  Q  T  L  E  M  P  P  K  G
Mus musculus 
Genomic GCGGAGGACATACCTGTGGGGCCTGAGGGGTCCTTTTGCTAGCACCGGAACAGTTGCCGGAGAGTTCATCCGCCAGCTTAAGAGATGCCGCCGAAGGGG
Protein A  E  D  I  P  V  G  P  E  G  S  F  C Stp H  R  N  S  C  R  R  V  H  P  P  A Stp E  M  P  P  K  G
Xenopus tropicalis 
Genomic CGATCCCGGAAGTGCAAACTCCAGACCCGGTGACGTCACACGTGCGACTGGCGCCCCGAATAGTCGCGGAGAGTGGAAGGAACCATGCCGCCAAAGGGG
Protein    R  S  R  K  C  K  L  Q  T  R Stp R  H  T  C  D  W  R  P  E Stp S  R  R  V  E  G  T  M  P  P  K  GBMC Molecular Biology 2006, 7:9 http://www.biomedcentral.com/1471-2199/7/9
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Bank:NM_006223] as well as the coding sequence of
Par17-RS were used as query. Only 5' clones exceeding an
overlap of 50 nt with the original cDNA entry without
intronic sequence were aligned within the BioEdit soft-
ware http://www.mbio.ncsu.edu/BioEdit/bioedit.html.
Genomic sequences of Parvulin homologs from 13 differ-
ent species (Homo sapiens, Mus musculus, Pan troglodytes,
Bos taurus, Canis familiaris, Gallus gallus, Tetraodon nigro-
viridis, Fugu rubripes, Xenopus tropicalis, Caenorhabditis ele-
gans, Drosophila melanogaster, Danio rerio and Anopheles
gambiae) were retrieved from the Ensembl genome
browser http://www.ensembl.org. Exons and neighboring
intronic sequences (+ 200 nt) were aligned within the
BioEdit software http://www.mbio.ncsu.edu/BioEdit/
bioedit.html. GC content and CpG ratio were determined
for an area of 500 nt surrounding the transcription start
site and 500 nt downstream of the stop codon as a refer-
ence. The CpG ratio is defined as (observed CG dinucle-
otides/expected CG dinucleotides). A CpG island
according to [24] is defined as a sequence longer than 200
nt with a CpG ratio above 0.6 and a GC content of more
than 50%.
mRNAs and primers for RT-PCR
DNA-free total RNAs for human tissues (kidney, small
intestine, brain, blood vessel, mammary gland and skele-
tal muscle) were purchased from Biocat BioChain Insti-
tute (Hayward, CA, USA). cDNAs from parotis and
submandibularis glands were kindly provided by Dr.
Veronika Homann and liver cDNA by Dr. Frank ter Veld.
Total RNA from Caco-2 and HTB cells was isolated using
RNAeasy kits (Qiagen, Hilden) according to manufac-
turer's instructions. Preceding cDNA synthesis with Super-
script II reverse transcriptase (Invitrogen, Karlsruhe), all
samples were incubated with DNAse to remove any trace
of genomic DNA. PCR was performed subsequently using
Taq Polymerase (NEB, Frankfurt) with the following
primers (5' to 3'): 246, atgcccatggcggggcttctaaag; 247,
gaaaagcggggaaagggggagcag and 248, cagtctttcatatgattttattt-
tcttccttcgacc, all showing similar melting points. PCR
products were analyzed on agarose gels and eluted bands
were sequenced.
Real-time PCR
To quantify relative amounts of Parvulin transcripts real-
time PCR primers were designed using the ABI program
Primer Express. To detect the longer transcript the follow-
ing primers were used (5' to 3'): 251, cggctttcaggcatttgtttag
and 252, gcggcatcttggaagcttgtt. Total amount of Parvulin
transcripts was detected with primers 253, tgggagtgacagt-
gctgacaa and 254, catgtttttcacatagaatgtgtctgac. Real-time
PCR was performed with SYBR green kits (Qiagen,
Hilden) on a GeneAmp 5700 sequence detection system
(Applied Biosystems, Perkin Elmer). Uniformity of PCR
products was verified by gel analysis and melting curve
analysis. Relative PCR efficiencies were determined using
dilution series of RT-PCR products as standard. All reac-
tions were performed in triplicate. As Ct values are at a
logarithmic scale, they were averaged to their geometric
mean values; errors are given as standard deviations.
Cell lysates, antibodies and Western blotting
HepG2 cells (Tumorbank, DKFZ Heidelberg) were culti-
vated in RPMI 1640 + 10% FBS, 1% Penicillin/Streptomy-
cin at 37°C and 5% CO2. HeLa cells (ATCC, USA) were
cultivated in DMEM with 25 mM Glucose + 10% FBS, 1%
L-Glutamine, 1% MEM at 37°C and 5% CO2. Cells were
grown to confluency in 100 mm petri-dishes, washed with
PBS and harvested into PBS + protease inhibitor mix on
ice (Complete without EDTA, Roche Diagnostics, Man-
nheim). Pelleted cells after 5 min at 400 × g and 4°C from
4 plates were resuspended in 0.5 ml PBS + Complete,
lysed by sonication and frozen at -20°C until use.
Equal amounts of protein were separated on 4 to 12% gra-
dient SDS gels (Invitrogen, Karlsruhe) with MES running
buffer including 0.5 M 2-mercaptoethanol and transferred
to nitrocellulose membrane. Blocking was done in PBS
with 1 or 2% BSA with or without 0,05% Tween. An
antiserum (#4113) raised against a mixture of KGLVR-
QLERFS and KGLVRQLEQFR peptides (SeqLab, Göttin-
gen) was used for detection of Par17 expression at 1:500
dilution in PBS + 1% BSA. Par17-QR and -RS reading
frames were subcloned into pET-28 with His6 fusion and
thrombin cleavage site. Recombinant proteins were
expressed in E. coli, purified on Ni-NTA columns and cou-
pled to CNBr-activated sepharose (Sigma) according to
the manufacturer's protocol. This Par17 column was used
for affinity purification of final bleeding of polyclonal
antibody #4113 ("Ab-EXT"). For comparison the polyclo-
nal antibody against Parvulin's PPIase domain was used
as described [11,12]. For characterization of Par17's mod-
ification rabbit anti-SUMO-1 (Santa Cruz, USA, 1:100
dilution), rabbit anti-SUMO-2/3 (Zytomed, Berlin, 1:50)
and mouse monoclonal anti-ubiquitin (Covance, Berke-
ley, USA, 1:50) antibodies were used at the indicated dilu-
tions. HRP conjugated anti-rabbit and anti-mouse
antibodies together with ECL kits (Amersham Bioscience,
Freiburg) were used for detection with a chemilumines-
cent camera (Bio-Rad, Munich). Stripping of Western blot
membranes was either done with stripping reagent
(Pierce) or two incubation steps in 2% SDS at 65°C.
In vitro translation and proteinase K digestion
For in vitro translation experiments the coding sequence
for Parvulin isoforms was amplified from RT-PCR prod-
ucts using the primers (5' to 3') 300 F (aaaaaagaattcgccac-
catgcccatggcggggcttctaaag) and 258
(acacacctcgagattattttcttccttcgaccataataat) for Par17-RS and
Par17-QR forms; Par14 was amplified with primers 304 FBMC Molecular Biology 2006, 7:9 http://www.biomedcentral.com/1471-2199/7/9
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(aaaaaagaattcgccaccatgccgcccaaaggaaaaagtggt) and 258
(Kozak sequence within forward primers 300 F and 304 F
is underlined). PCR products were TA TOPO cloned into
pCR-4 (Invitrogen, Karlsruhe). Correct orientation of
inserts relative to the T7 promoter was verified by restric-
tion analysis and DNA sequencing. The resulting con-
structs were used for in vitro transcription and translation
reactions with 35S-methionine incorporation (ICN,
Eschwege, Germany) using the coupled TNT reticulocyte
lysate system (Promega, Mannheim) according to the
manufacturer's instructions. The lysates were separated on
17.5% SDS gels following autoradiography. For limited
proteolysis studies, lysates were incubated with varying
concentrations of proteinaseK at 10°C for 30 min, reac-
tions were stopped by an excess of PMSF and also analyses
by SDS-PAGE and autoradiography.
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